• 1. Influence of 8-week daily consumption of a new product combining green coffee hydroxycinnamates and beta-glucans on polyphenol bioavailability in subjects with overweight and obesity
  Miguel ángel Seguido,Rosa María Tarradas,Susana González-Rámila,Joaquín García-Cordero,Beatriz Sarriá,Laura Bravo-Clemente,Raquel Mateos Food Funct. 2022 13 1133
• 2. A new method for simultaneous determination of 14 phenolic acids in agricultural soils by multiwavelength HPLC-PDA analysis
  Jia Cheng,Chunfu Zhou,Yue Xie,Min Wang,Cheng Zhou,XiaoShuang Li,YaDong Du,Fan Lu RSC Adv. 2022 12 14939
• 3. Synthesis and biological evaluation of phosphatidylcholines with cinnamic and 3-methoxycinnamic acids with potent antiproliferative activity
  Marta Czarnecka,Marta ?witalska,Joanna Wietrzyk,Gabriela Maciejewska,Anna Gliszczyńska RSC Adv. 2018 8 35744
• 4. Bioavailability of red wine and grape seed proanthocyanidins in rats
  Gema Pereira-Caro,Sylvie Gaillet,José Luis Ordó?ez,Pedro Mena,Letizia Bresciani,Keren A. Bindon,Daniele Del Rio,Jean-Max Rouanet,José Manuel Moreno-Rojas,Alan Crozier Food Funct. 2020 11 3986
• 5. Understanding the role played by protic ionic liquids (PILs) and the substituent effect for enhancing the generation of Z-cinnamic acid derivatives
  Rocío B. Rodríguez,Ramiro L. Zapata,María L. Salum,Rosa Erra-Balsells Photochem. Photobiol. Sci. 2020 19 819

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Cinnamic acids and derivatives Coumaric acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Cinnamic acids and derivatives Hydroxycinnamic acids and derivatives Coumaric acids and derivatives

Recent Advances in the Study of 3-(3-Methoxyphenyl)prop-2-enoic Acid (CAS: 17570-26-2) in Chemical Biology and Pharmaceutical Research

3-(3-Methoxyphenyl)prop-2-enoic acid (CAS: 17570-26-2) is a bioactive compound that has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. This cinnamic acid derivative, characterized by its methoxy-substituted phenyl ring and α,β-unsaturated carboxylic acid moiety, exhibits a range of biological activities, including anti-inflammatory, antioxidant, and anticancer properties. Recent studies have explored its molecular mechanisms, synthetic pathways, and therapeutic potential, positioning it as a promising candidate for drug development.

One of the key areas of research focuses on the compound's role as a modulator of cellular signaling pathways. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that 3-(3-methoxyphenyl)prop-2-enoic acid inhibits the NF-κB pathway, a critical regulator of inflammation and immune responses. The study utilized in vitro models of human macrophages and showed that the compound significantly reduced the production of pro-inflammatory cytokines such as TNF-α and IL-6. These findings suggest its potential as a lead compound for developing novel anti-inflammatory agents.

In addition to its anti-inflammatory effects, recent investigations have highlighted the compound's antioxidant properties. A 2024 paper in Free Radical Biology and Medicine reported that 3-(3-methoxyphenyl)prop-2-enoic acid scavenges reactive oxygen species (ROS) and enhances the activity of endogenous antioxidant enzymes, such as superoxide dismutase (SOD) and catalase. These effects were observed in both cellular and animal models, indicating its potential for mitigating oxidative stress-related diseases, including neurodegenerative disorders and cardiovascular conditions.

The anticancer potential of 3-(3-methoxyphenyl)prop-2-enoic acid has also been a focal point of recent research. A study published in Cancer Research in early 2024 revealed that the compound induces apoptosis in several cancer cell lines, including breast and colon cancer, by activating the intrinsic mitochondrial pathway. Mechanistic studies identified the compound's ability to upregulate pro-apoptotic proteins such as Bax and downregulate anti-apoptotic proteins like Bcl-2. These findings underscore its potential as a chemotherapeutic agent or adjuvant therapy.

From a synthetic chemistry perspective, advancements have been made in optimizing the production of 3-(3-methoxyphenyl)prop-2-enoic acid. A 2023 study in Organic & Biomolecular Chemistry described a novel catalytic method for its synthesis using palladium-catalyzed cross-coupling reactions, which improved yield and purity compared to traditional methods. This development is critical for scaling up production for preclinical and clinical studies.

Despite these promising findings, challenges remain in the development of 3-(3-methoxyphenyl)prop-2-enoic acid as a therapeutic agent. Issues such as bioavailability, metabolic stability, and potential off-target effects need to be addressed through further pharmacokinetic and pharmacodynamic studies. Ongoing research is exploring structural modifications and formulation strategies to enhance its drug-like properties.

In conclusion, 3-(3-methoxyphenyl)prop-2-enoic acid (CAS: 17570-26-2) represents a versatile compound with significant potential in chemical biology and pharmaceutical applications. Recent studies have elucidated its mechanisms of action, synthetic routes, and therapeutic benefits, paving the way for future drug development efforts. Continued research will be essential to fully realize its clinical potential and overcome existing challenges.

• 6099-04-3(3-Methoxycinnamic acid)
• 16909-11-8(3,5-Dimethoxycinnamic acid)
• 4361-94-8(2-Propenoic acid,3-[4-(4-hydroxyphenoxy)phenyl]-)
• 6500-63-6(5-(3-Methoxyphenyl)penta-2,4-dienoic acid)
• 103986-73-8(trans-3-Ethoxycinnamic Acid)
• 830-09-1(3-(4-methoxyphenyl)prop-2-enoic acid)
• 943-89-5((E)-3-(4-Methoxyphenyl)acrylic acid)
• 77124-20-0(3-(3-Phenoxyphenyl)acrylic Acid)
• 86636-96-6(Potassium 4-Methoxycinnamate)
• 717910-83-3(3-(4-phenoxyphenyl)prop-2-enoic acid)